
Overview
Utah Medical Q2 2025 revenue falls 4.3% yr/yr, driven by lower PendoTECH sales
Company's gross profit margin contracts due to lower sales, unfavorable product mix
Share repurchases help mitigate EPS decline despite revenue and profit challenges
Outlook
Company expects 2H 2025 PendoTECH sales to be $200 lower than 2H 2024
Utah Medical projects 2025 sales to PendoTECH $2 mln lower than 2024
Result Drivers
PENDOTECH SALES DECLINE - Major driver of revenue drop with sales $315 lower in Q2 2025 compared to Q2 2024
UNFAVORABLE PRODUCT MIX - Gross profit margin contracted due to lower sales and product mix issues in Ireland
LITIGATION COST REDUCTION - Operating income decline was less severe due to $355 lower litigation costs in Q2 2025
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales |
| $9.95 mln |
|
Q2 EPS |
| $0.94 |
|
Q2 Net Income |
| $3.05 mln |
|
Q2 Gross Profit |
| $5.60 mln |
|
Q2 Operating Income |
| $3.20 mln |
|
Q2 Pretax Profit |
| $3.84 mln |
|
Press Release: ID:nACSxzpHca